ArticleThe oncologist2025
Adjuvant transarterial chemoembolization plus lenvatinib for patients with HCC with MVI after resection: a multicenter retrospective study.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMicrovascular invasion (MVI) is a critical prognostic factor affecting long-term survival in patients with hepatocellular carcinoma (HCC). Despite its clinical significance, the optimal postoperative adjuvant therapy for HCC patients with MVI remains undefined. This study aimed to evaluate the efficacy and safety of postoperative adjuvant transarterial chemoembolization (PA-TACE) combined with lenvatinib vs PA-TACE alone in HCC patients with MVI.
methodsWe conducted a retrospective analysis of consecutive HCC patients with MVI who underwent curative-intent resection followed by either PA-TACE alone or PA-TACE plus lenvatinib between 2018 and 2022. To ensure comparability, baseline characteristics were balanced using 1:1 propensity-score matching (PSM). The study outcomes, overall survival (OS) and recurrence-free survival (RFS), were compared between the two treatment groups.
resultsThe study included 192 patients, with 106 in the PA-TACE alone group and 86 in the PA-TACE plus lenvatinib group. After PSM, 66 matched pairs were analyzed. The median OS and RFS in the PA-TACE plus lenvatinib group were significantly longer than those in the PA-TACE alone group (43.6 months vs 24.0 months, P = 0.015; and 19.6 months vs 10.2 months, P = 0.025, respectively). Multivariable analysis confirmed that PA-TACE plus lenvatinib was an independent protective factor for both OS and RFS.
conclusionsThe combination of PA-TACE and lenvatinib significantly improves survival outcomes in HCC patients with MVI following curative liver resection compared to PA-TACE alone. These findings suggest that this combined approach may be a more effective adjuvant therapy for this high-risk patient population. Further studies are necessary to validate these results and establish clinical guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.